Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a sell rating to a hold rating in a research report report published on Saturday.

Several other brokerages have also recently issued reports on ACRS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Friday, March 27th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Aclaris Therapeutics in a report on Thursday, March 19th. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Aclaris Therapeutics in a research note on Tuesday, March 31st. Finally, Craig Hallum assumed coverage on shares of Aclaris Therapeutics in a report on Friday, January 30th. They issued a “buy” rating and a $10.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $9.80.

Aclaris Therapeutics Stock Performance

Shares of NASDAQ ACRS opened at $4.20 on Friday. Aclaris Therapeutics has a 1-year low of $1.05 and a 1-year high of $4.89. The firm has a market capitalization of $506.50 million, a P/E ratio of -7.92 and a beta of 0.67. The firm’s 50-day moving average price is $3.48 and its 200-day moving average price is $2.89.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.01). Aclaris Therapeutics had a negative return on equity of 52.04% and a negative net margin of 829.58%.The firm had revenue of $1.30 million during the quarter, compared to the consensus estimate of $2.07 million. Equities research analysts forecast that Aclaris Therapeutics will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Three Bridge Wealth Advisors LLC purchased a new position in shares of Aclaris Therapeutics in the 3rd quarter worth about $1,358,000. Squarepoint Ops LLC grew its position in shares of Aclaris Therapeutics by 11.9% during the 2nd quarter. Squarepoint Ops LLC now owns 390,583 shares of the biotechnology company’s stock valued at $555,000 after acquiring an additional 41,666 shares during the period. Intech Investment Management LLC purchased a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth approximately $64,000. The Manufacturers Life Insurance Company bought a new stake in shares of Aclaris Therapeutics in the 2nd quarter worth approximately $48,000. Finally, XTX Topco Ltd purchased a new position in Aclaris Therapeutics in the second quarter valued at approximately $34,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.